Pfizer disclosed that it would increase the price of 41 drugs; 37 drugs will see price increases of 5%, 1 drug by 9%, and 3 drugs by 3% on January 15, 2019. The announcement was met with pushback from politicians who have been vocal about drug pricing concerns.
In early November 2018, outgoing Pfizer CEO Ian Read announced that the company will be returning to “business as normal” in regard to its drug pricing in January 2019, after agreeing to hold off on price hikes due to pressure from the Trump administration earlier this year.
Within the announcement, Pfizer disclosed that it would increase the price of 41 drugs; 37 drugs will see price increases of 5%, 1 drug by 9%, and 3 drugs by 3% on January 15, 2019.
The announcement was met with pushback from politicians who have been vocal about drug pricing concerns. Earlier this week, Senator Tammy Baldwin, D-Wisconsin, sent a letter to Read, expressing concern over the pricing announcement and the implications it could have for patients and families.
“I am disappointed that your company has decided to continue playing political games and to raise prices once again in January instead of making a commitment to permanently reduce prescription drug prices for millions of families struggling to afford needed medications,” wrote Baldwin. Pfizer has yet to make a formal response.
This marks the second letter Baldwin has sent to Read in a matter of months. In the first letter, sent in July 2018 after Pfizer announced it would halt on raising prices, Baldwin implored the company to stop “playing games with the costs of prescription drugs that millions of Americans depend on,” and make the price reductions permanent.
In Baldwin’s most recent letter, she requests clarifications around the upcoming price hikes, such as, “What are the current list prices for each drug and what will the list prices be when price increases take effect in January?”; “Were these drugs subject to the price increase deferral that your company announced in July?”; and “For each product subject to price increases this year, please include information on: any changes in the cost of raw materials used in manufacturing; marketing and advertising expenditures; total expenditures on research and development,” among others.
“Leading drug companies’ continued inaction to address rising prices in a serious way is exactly why we need transparency and accountability,” wrote Baldwin. She cited transparency and accountability as “critical first steps” in tackling the high cost of drugs and was open to working together in order to solve the problem.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.